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It has been shown that all selectins recognize the carbohydrate epitopes sialyl Lewisx and sialyl Lewisa. For the estab-
lishment of the structure-activity relationship, the efficient synthesis of these tetrasaccharides and derivatives is therefore
of vital interest. The glycosyl transferase-mediated approach is summarized with emphasis on the use of modified
acceptors and modified sugar-nucleotide donors. A survey of the involved enzymes: b(1-3) and b(1-4)galactosyl trans-
ferases, a(2-3)sialyl transferase, FucT III and FucT VI reveals that the enzymatic synthesis is highly efficient for the rapid
preparation of sialyl Lewisx- and sialyl Lewisa-derivatives.
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1. Introduction
The recent interest in the preparation of natural and modi-
fied oligosaccharide structures stems from the numerous
demonstrations of their potential as pharmaceuticals [1].
Selected examples are in the area of infectious diseases [2],
cancer [3], inflammation [4] or vaccines [5].
This  review  focusses on the application  of enzymatic
methods to prepare modified natural carbohydrate epi-
topes with the potential to inhibit the inflammatory cas-
cade [6].
Numerous diseases and pathological situations are re-
lated to excessive influx of leukocytes into tissues. Al-
though this influx normally represents an essential defence
mechanism against  infection, excessive or inappropriate
leukocyte accumulation results in injury to host tissues as
observed  in ischemia-reperfusion injury, respiratory dis-
ease, dermatitis or gastro-intestinal inflammation [7].
Early in the inflammatory response, leukocytes adhere
to and roll along endothelial cells on the inner surface of
blood vessels. It has been clearly shown that an inducible
set of calcium dependent adhesion molecules, the selectins,
mediates this initial event [8]. Since leukocyte rolling is a
prerequisite for later inflammatory events, blocking select-
ins offers a valuable strategy for preventing the deleterious
consequences of excessive leukocyte influx.
It was shown that all selectins recognize the common
carbohydrate epitope sialyl Lewisx (1), albeit with different
affinities [9]. In addition, it was firmly established that the
selectins also bind sialyl Lewisa (2) [10]. These two tetra-
saccharides have, therefore, served as lead structures in our
search for selectin  antagonists with increased biological
activity, simplified structures and improved bioavailability
[11].
The advantages of using glycosyl transferases for oli-
gosaccharide synthesis  have been well reviewed [12,13]
and arise mostly from the mild reaction conditions, the
lack of requirement for protection and deprotection steps
and the regio- and stereoselectivity of the glycosylation
step.
In order to take advantage of these biocatalysts for the
synthesis of sialyl Lewisx,  sialyl Lewisa and derivatives
thereof, two prerequisites have to be fulfilled: the glycosyl
transferases and the sugar nucleotides (nucleotide mono-
and diphosphate sugars) have to be available on a prepara-
tive scale.
2. Glycosyl transferases and sugar nucleotides
The Leloir-transferases [14] are key enzymes in the ana-
bolic glycosylation pathway. They transfer a monosaccha-
ride moiety from nucleotide-activated donor sugars regio-
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and stereospecifically to a growing oligosaccharide chain.
Although nature has developed an almost unlimited
number of donor sugars, mammalian cells form their vast
variety of cell surface carbohydrates with only eight donor
substrates [15,16]. In this review we will focus on the
chemo-enzymatic synthesis of sialyl Lewisx, sialyl Lewisa
and derivatives thereof. The glycosyl transferases and the
sugar nucleotides involved are summarized in Figures 1
and 2a–c.
A growing number of publications dealing with the syn-
thesis of non-natural sugar nucleotides have recently ap-
peared. The chemical and/or enzymatic synthesis of these
activated donors and various derivatives thereof have been
reviewed [16]. Not all of these donors, however, have been
probed on the respective transferases. Specificities of trans-
ferases towards structural modifications of sugar nucleo-
tides [13,35] are summarized below:
b(1–4)Galactosyl transferase tolerates small non-polar
replacements of the 2- and 6-OH-group in UDP-galactose
[20,23]. a(2–3)Sialyl transferase, either isolated from rat
liver or cloned and overexpressed by CHO cells, transfers
sialic acid derivatives, in which the natural 5-N-acetyl group
is replaced by non-natural acyl variants including polar and
lipophilic residues [25,26]. The 9-OH-group of the sialic
acid does not interact with the enzyme and can, therefore,
be derivatized by polar and/or bulky aromatic residues.
This observation was applied to specifically label oligosac-
charides via sialylation [27]. Finally, a(1-3/4)fucosyl trans-
ferase tolerates quite bulky attachments on the 6-position
of fucose [33,34]. When the 2- and the 3-OH-group in
GDP-fucose are replaced by small substituents [29,30,31],
the corresponding sugar nucleotides still act as donors for
a(1-3/4)fucosyl transferase.
3. Enzymatic synthesis of sialyl Lewisx (sLex)
derivatives
3.1. Galactosylation of non-natural substrates with
b(1–4) galactosyl transferase
The most intensively studied transferase with respect to
donor- and acceptor specificity is b(1–4)galactosyl trans-
ferase (GalT E.C.2.4.1.22/38) [13,36]. This enzyme transfers
D-galactose from UDP-galactose b-selectively onto the 4-
position of terminal N-acetylglucosamine to produce N-
acetyllactosamine (see Scheme 1). In the presence of
a-lactalbumine the specificity is altered and D-glucose can
be used as the acceptor [13,22]
In a structure-activity study aimed at identifing the phar-
macophores of sLe3, we applied standard galactosylation
conditions [37] to a series of N-acylglucosamine derivatives
with various substitutions on the reducing end [38]. The
selected examples (see Table 1) show that lipophilic agly-
cons (e.g., entry 2, 4) as well as protected peptide moieties
(entries 6, 7) or alkaloids (entry 5) are tolerated. The only
limitation to enzymatic galactosylation is the solubility of
the acceptor in the incubation buffer [38]. An attractive
82
Figure 1. Glycosyl transferases and sugar nucleotides involved in the enzymatic synthesis of sialyl Lewisx and sialyl Lewisa
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Figure 2a. Selected protocols for the synthesis of UDP-Gal and non-natural derivatives
Figure 2b. Selected protocols for the synthesis of CMP-Sia and non-natural derivatives
Figure 2c. Selected protocols for the synthesis of GMP-Fuc and non-natural derivatives
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application of this enzymatic glycosylation technique is the
efficient galactosylation of di- and/or oligovalent acceptor
compounds [39,40].
b(1–4)Galactosyl transferase shows also an unexpect-
edly broad tolerance towards non-natural N-acyl residues
of the acceptor substrate [36,41,46]. Preparatively useful
yields have been obtained with bulky (entries 10, 13, 14)
or charged substituents (entries 11, 12). Moreover, the acyl
group can for example be replaced by a sulfonamide (en-
try 9). These results indicate a high flexibility of
b(1–4)galactosyl transferase towards their substrates.
Whereas this property is useful for large scale preparation,
it impedes the rational design of b((1–4)galactosyl trans-
ferase inhibitors [47,48].
3.2. Sialylation of non-natural substrates with
a(2–3)sialyl transferase
Chemical sialylations suffer from poor stereoselectivity
and low overall yields. This is due to the low reactivity of
the tertiary anomeric carbon and the lack of neighboring
group assistance [49]. With a(2–3)sialyl transferase
(E.C.2.4.99.6), however, sialic acid is transferred from
CMP-sialic acid a-selectively onto the 3-OH group of a
terminal galactose (see Scheme 2).
All of the hydroxyl groups of the galactose unit are es-
sential for substrate recognition by the sialyl transferase
[13]. The enzyme does, however, accept a wide variety of
acyl groups on the lactosamine nitrogen [36]. The replace-
ment by aromatic or heteroaromatic moieties (entries 3, 7),
Table 1. Glucosamine derivatives tolerated as substrates by b(1–4)galactosyl transferase
Scheme 1. Transfer of galactose to glucosamine derivatives by b(1–4)galactosyl transfer (R9 5 (CH2)8COOMe)
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charged residues (entries 4, 5) or sulfonamides (entry 6)
[50] is well tolerated. Bulky polar monosaccharides (entry
8) are also easily sialylated in the expected manner [46].
Thus, libraries of sialylated type II sugars—the immediate
precursors of the sialyl-Lewisx-tetrasaccharides—are pro-
duced rapidly with good overall yields.
3.3 Fucosylation of non-natural substrates with
a(1–3)fucosyl transferase (FucT VI)
For the final fucosylation (Scheme 3) of the sialyl
a(2–3)lactosamide derivatives recombinant FucT VI was
used [51]. FucT VI transfers fucose (Table 3a) as well as
fucose derivatives (Table 3b) a-selectively onto the 3-OH
group of a N-acyl glucosamide moiety.
The results using modified substrates are summarized in
Table 3a. Surprisingly, the natural N-acetyl group of the
glucosamine unit is not a key recognition element for FucT
VI, although fucosylation takes place at the hydroxyl group
adjacent to the N-acyl position [52]. Small (entry 2) or
bulky aromatic residues (entries 3, 7) are accepted. In addi-
tion, charged substituents (entry 5) [52], a bulky polar
monosaccharide (entry 8) [46] or even a sulfonamide (en-
try 6) [52] are tolerated. Moreover (see Table 3b), the con-
comitant replacement of the natural N-acetyl group and
the L-fucose donor by non-natural N-acyl moieties and
D-arabinose (entries 9a–12a) or L-galactose (entries
9b–12b), respectively, is well accepted by FucT VI [53].
Thus, sLex-libraries differing in two positions at the same
time can be obtained enzymatically for lead discovery or
lead optimization programs.
4. Enzymatic synthesis of sialyl Lewisa (sLea)
derivatives
4.1. Galactosylation of non-natural substrates with
b(1–3)galactosyl transferase
sLea is a structural isomer of sLex with interchanged attach-
ment of D-galactose and L-fucose to the glucosamine. The
enzymatic assemblage starts with the transfer of D-galac-
tose catalyzed by b(1–3)GalT to the 3-position of a termi-
nal N-acetylglucosamine (see Scheme 4) yielding a type I
(Lewisc) disaccharide.
Only one report concerning the substrate specificity of
b(1–3)galactosyltransferase [54] has so far been published.
Interestingly, the natural N-acetylgroup of the glucosamide
acceptor (entry 1) can be replaced by small aliphatic acyl
residues (entries 2–4,6) or polar and charged amides (entry
5) (see Table 4). Despite the close proximity of those vari-
ations to the site of galactosylation acceptable yields of a
number of Lec-derivatives are obtained.
Table 2. Type II disaccharides tolerated as substrates by a(2–3)sialyl transferase (R9 5 (CH2)8COOMe)
Scheme 2. Enzymatic sialylation of type II disaccharides (R 5 (CH2)8COOMe)
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4.2. Sialylation of non-natural substrates with a(2–3)
sialyl transferase
The type II and type I disaccharides are likewise substrates
for the rat liver a(2–3)sialyltransferase [13]. Both disaccha-
rides are a-selectively sialylated at the 3-position of the
terminal galactose (see Scheme 5).
As observed for the type II chain (see section 3.2),
a(2–3)SiaT does not interact N-acyl groups in the type I
chain (Table 5). The natural N-acetyl group can for exam-
ple be replaced by aromatic or heteroaromatic (entries 5,
6) or charged amide residues (entries 3, 4) [55]. Even sul-
fonamides (entry 7) and bulky saccharides (entry 8) do not
impede the proper sialylation [46].
4.3. Fucosylation of non-natural substrates with
a(1–4) fucosyl transferase (FucT III)
A final incubation of sLec with fucosyl transferase III yields
the target sLea. FucT III transfers L-fucose a-selectively
from GDP-fucose onto the 4-position of the N-acetylglu-
cosamine residue (see Scheme 6).
Table 3a. Fucosylation of non-natural N-acylglucosamides with GDP-fucose
Table 3b. Fucosylation of non-natural N-acylglucosamides with
non-natural GDP sugars
GDP-Fuc
Scheme 3. Enzymatic a(1–3)glycosylation with fucosyl transferase VI(R9 5 (CH2)8COOMe)
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Scheme 4. Transfer of galactose to glucosamine derivatives by b(1–3)galactosyl transferase (R9 5 (CH2)8COOMe)
Table 4. b(1–3)Galactosylation of non-natural glucosamides (R9 5 (CH2)8COOMe)
Scheme 5. Enzymatic sialidation of type I disaccharides (R9 5 (CH2)8COOMe)
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Table 5. Type I disaccharides tolerated by a(2–3)sialyl transferase (R9 5 (CH2)8COOMe)
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GDP-Fuc
Scheme 6. Enzymatic a(1–3)glycosylation with fucosyl transferase III (R9 5 (CH2)8COOMe)
Table 6. Fucosylation of non-natural N-acylglucosamides with GDP-fucose and non-natural GDP-sugars.
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Recent investigations revealed key polar groups on the
sugar nucleotide and the acceptor substrates recognized by
the enzyme [13,56]. Since the N-acetyl residue of the glu-
cosamine moiety is not essential for recognition by the
transferase, it is open for wide modifications.
Selected examples are presented in Table 6 [55]. Small
neutral (entries 1–3) or charged (entry 4) amide residues
are well tolerated. Bulky aromatic residues are accepted
even in combination with non-natural fucose donors (en-
tries 5–7). Tetrasaccharide (entry 8) is also fucosylated in
high yield. Thus the transfer of non-natural donors onto
non-natural acceptors opens an elegant access to sLea-li-
braries with altered on fucose and glucosamine moieties.
5. Outlook
In the reviewed examples, the glycosyl transferases were
found to have a remarkable flexibility in the recognition of
both the sugar nucleotide donors and the acceptor sub-
strates. In many cases the reaction rates are very low com-
pared to the natural reaction. Such rates, however, proved
to be sufficient for the synthesis of preparative amounts of
oligosaccharide derivatives.
In cases where modifications on both the sugar nucleo-
tide and the acceptor substrate are tolerated by the glycosyl
transferases, the enzymatic synthesis offers an efficient ap-
proach to thematic or random oligosaccharide libraries.
A severe drawback for the feasibility of the enzymatic
synthesis of oligosaccharides and derivatives thereof stems
from the availability of glycosyl transferases and sugar nu-
cleotides. Although an increasing number of transferases
are commercially available, they are still prohibitively ex-
pensive, particularly for synthesis on a preparative scale.
For this reason, a growing number of industrial and aca-
demic laboratories have initiated programs to clone and
overexpress their own transferases for mechanistic and
synthetic studies.
Since the commercially available sugar nucleotides are
also prohibitively expensive, numerous chemical and
chemo-enzymatic approaches for their syntheses have
been developed in recent years. They have decisively im-
proved the availability of activated sugars in preparative
amounts and therefore the feasibility of the enzymatic syn-
thesis of oligosaccharides and derivatives thereof.
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